News

On Point Webinar Series

Did you miss the inaugural On Point webinar discussing how the use of radiology and advanced technologies can be used to measure response for COVID-19 treatments and vaccines and lead to better decisions? Visit https://imagingendpoints.com/on-point/ for an on-demand version of…   Read More

Promising Glioma Results

Forma Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced recently that the company’s investigational IDH1m inhibitor, olutasidenib, demonstrated a preliminary disease control rate of 50% in heavily pre-treated patients with predominantly enhancing, recurrent mIDH1…   Read More